目的 研究參麥注射液體內(nèi)外抗腫瘤作用。方法 以小鼠肉瘤S180、肝癌H22、Lewis肺癌實(shí)體瘤模型考察參麥注射液的體內(nèi)抑瘤作用；通過MTT法考察參麥注射液體外對人宮頸癌HeLa細(xì)胞和人肝癌HepG 2細(xì)胞的增殖抑制作用。結(jié)果 參麥注射液在體內(nèi)對小鼠肉瘤S180、肝癌H22、Lewis肺癌均有顯著的抑制作用，且呈劑量相關(guān)性，中、高劑量抑瘤率可達(dá)35%以上；體外對人宮頸癌HeLa細(xì)胞和人肝癌HepG 2細(xì)胞亦有增殖抑制作用，且呈濃度–時間相關(guān)性，48 h的IC50值分別為0.36、0.72 g /mL，72 h的IC50值分別為0.21、0.29 g /mL。結(jié)論 參麥注射液體內(nèi)外均有顯著的抗腫瘤活性。

Objective To investigate the antitumor effect of Shenmai Injection in vitro and in vivo. Methods Solid tumor models of mouse sarcoma S180, hepatoma H22, and Lewis lung carcinoma were used to study the antitumor effect of Shenmai Injection in vivo. MTT assay was used to examine its inhibitory effect on the proliferation of HeLa cell and HepG 2 cells. Results Shenmai Injection showed obviously inhibitory effect on the growth of S180, H22, and Lewis in tumor-bearing mice in a dose-dependent manner, and inhibitory rates in mid- and high-dose groups were over 35%. Shenmai Injection also inhibited the proliferation of HeLa cells and HepG 2 cells in vitro, showing a concentration-time correlation. The IC50 values of 48 h were 0.36 and 0.72 g/mL and the IC50 values of 72 h were 0.21 and 0.29 g/mL. Conclusion Shenmai Injection has remarkable antitumor activity both in vitro and in vivo.